- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01682746
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults. There are currently few cases published involving the use of PDT in infratentorial (in the posterior fossa) brain tumors in general and specifically those occurring in children. The investigators propose to test a technique, for the first time in the U.S., that demonstrated in Australian adult glioblastoma patients dramatic long-term, survival rates of 57% (anaplastic astrocytoma) and 37% (glioblastoma multiforme). These results are unprecedented in any other treatment protocol.
Photodynamic therapy (PDT) is a paradigm shift in the treatment of tumors from the traditional resection and systemic chemotherapy methods. The principle behind photodynamic therapy is light-mediated activation of a photosensitizer that is selectively accumulated in the target tissue, causing tumor cell destruction through singlet oxygen production. Therefore, the photosensitizer is considered to be the first critical element in PDT procedures, and the activation procedure is the second step. The methodology used in this proposal utilizes more intensive laser light and larger Photofrin photosensitizer doses than prior PDT protocols in the U.S. for brain tumor patients. The PDT will consist of photoillumination at 630 nm beginning at the center of the tumor resection cavity, and delivering a total energy of 240 J cm-2. The investigators feel that the light should penetrate far enough into the tissue to reach migrating tumor cells, and destroy these cells without harming the healthy cells in which they are dispersed.
The investigators will be testing the hypothesis that pediatric subjects with progressive/recurrent malignant brain tumors undergoing PDT with increased doses of Photofrin® and light energy than were used in our previous clinical study will show better progression free survival (PFS) and overall survival (OS) outcomes. PDT will also be effective against infratentorial tumors. The specific aims include determining the maximum tolerable dose (MTD) of Photofrin in children and looking for preliminary effectiveness trends.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Wauwatosa, Wisconsin, United States, 53226
- Children's Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Age: ≥ 6 months and < 18 years
- Disease: Patients with relapsed or refractory brain tumors are eligible. Patients must have had histologic verification of malignancy at original diagnosis or relapse. Tumors can be either supratentorial or infratentorial (posterior fossa) in location.
- Disease Status: Patients must have potentially resectable disease.
- Therapeutic Options: Patients' current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life.
- Performance Level: Karnofsky 50% or greater for patients > 16 years of age and Lansky 50 or greater for patients < 16 years of age. Note: Neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
- Predictable Life Expectancy: > 8 weeks
- Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy. At least 3 weeks from previous chemotherapy and 4 weeks from prior radiation therapy
Organ Function:
Adequate bone marrow function
Absolute neutrophil count ≥ 1,000
Platelet count ≥ 100,000 (may transfuse to meet requirement)
Adequate renal function
Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2 OR
A serum creatinine within normal range based on age/gender
Adequate liver function Bilirubin (direct) ≤ 3X upper limit of normal (ULN) for age
SGPT (ALT) ≤ 10X ULN
For the purpose of this study, the ULN for SGPT is 45 U/L
Serum albumin ≥ 2 g/dL
Adequate coagulation
PT and INR ≤ 2X ULN for age
- Central Nervous System Function: Patients with seizure disorder may be enrolled if receiving non- enzyme inducing anticonvulsants and well controlled.
- Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
- Archival tumor tissue slides from initial diagnosis should be reviewed by CHW institutional pathologists prior to study enrollment whenever possible.
Exclusion Criteria
- Disseminated disease (metastatic disease)
- Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study, as risks of fetal and teratogenic adverse effects of Photofrin® are not known.
- Other concurrent tumor therapy
- Subjects with porphyria
- Subjects taking potentially photosensitizing drugs
- The presence of adverse events of neurologic function, photosensitivity, or photophobia Grade 4 or higher (CTCAE Version 4.0)
- Allergy to eggs, soybean oil, or safflower oil (due to potential allergy against intralipids)
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Photofrin (porfimer sodium) photodynamic therapy.
|
Intravenous (IV) Photofrin This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity & light precautions for a minimum of 30 days after the infusion. Photodynamic Therapy (PDT) After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerable dose (MTD) of Photofrin® in pediatric subjects
Time Frame: One to four weeks from PDT
|
MTD is defined as the Photofrin® dose that precedes the dose level used with a subgroup of subjects that exhibits a greater than 33% DLT occurrence. DLT is defined as any of the following events with reasonable possibility to be attributable to the experimental intervention:
|
One to four weeks from PDT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain tumor response
Time Frame: Response ocurring within 3 years after PDT
|
To preliminarily define the antitumor activity of Photofrin and laser light activation within the confines of a Phase 1 Study.
We will follow progression free survival and overall survival for 3 years post PDT treatment.
|
Response ocurring within 3 years after PDT
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Harry T Whelan, MD, Medical College of Wisconsin
- Principal Investigator: Jeff Knipstein, MD, Medical College of Wisconsin
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Brain Tumor
- GBM
- Photodynamic Therapy
- Medulloblastoma
- Ependymoma
- Glioblastoma
- Meningioma
- Chordoma
- PNET
- Astrocytoma
- Photochemotherapy
- Pilocytic Astrocytoma
- Low grade Astrocytoma
- Anaplastic Astrocytoma
- Germinoma
- Germ Cell Tumor
- CNS Lymphoma
- Craniopharyngioma
- Mixed Glioma
- Optic Nerve Glioma
- Oligodendroglioma
- Pituitary Tumors
- Desmoplastic Neuroepithelial Tumor
- DNET
- Non-germinaoma
- Brain Stem Glioma
- Subependymoma
- Metastatic Brain Tumors
- Primitive Neuroectodermal
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Disease Attributes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Recurrence
- Brain Neoplasms
- Antineoplastic Agents
- Photosensitizing Agents
- Dermatologic Agents
- Dihematoporphyrin Ether
- Trioxsalen
Other Study ID Numbers
- 163588-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Tumor, Recurrent
-
University of California, San FranciscoGilead SciencesSuspendedBrain Cancer | Malignant Brain Tumor | Brain Tumor Adult | Recurrent Brain Tumor | Progressive Malignant Brain Tumor | Brain Tumor, PediatricUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent... and other conditionsUnited States
-
Seattle Children's HospitalCures Within ReachUnknownRecurrent Childhood Brain TumorUnited States
-
Australian & New Zealand Children's Haematology...National Health and Medical Research Council, Australia; Secura Bio, Inc.TerminatedRhabdoid Tumor | Atypical Teratoid/Rhabdoid Tumor | Malignant Rhabdoid Tumor | Recurrent Brain Tumor, ChildhoodAustralia, New Zealand, United States
-
Loma Linda UniversityBlue Earth DiagnosticsRecruiting
-
University of Texas Southwestern Medical CenterNot yet recruitingRecurrent Brain Tumor, Childhood | Ketogenic DietUnited States
-
EpicentRx, Inc.Texas Children's Cancer CenterActive, not recruitingUnspecified Childhood Solid Tumor, Protocol Specific | Central Nervous System Neoplasms | Brain Tumor, Recurrent | Brain Tumor, PediatricUnited States
-
The University of Texas Health Science Center,...RecruitingBrain Tumor RecurrentUnited States
-
Sabine Mueller, MD, PhDWashington University School of Medicine; Nationwide Children's Hospital; Rally...Not yet recruitingPediatric Brain Tumor | Recurrent Pediatric Brain Tumor | Pediatric Supratentorial NeoplasmUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Active, not recruitingBrain Tumor, Recurrent | Brain Tumor, RefractoryUnited States
Clinical Trials on Photofrin (porfimer sodium) & photodynamic therapy.
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Carcinoma | Locally Advanced Head and Neck CarcinomaUnited States
-
University of MiamiCompletedHead and Neck Cancer | Precancerous/Nonmalignant ConditionUnited States
-
Ohio State University Comprehensive Cancer CenterWithdrawnStage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma
-
John DeWittAmerican Society for Gastrointestinal Endoscopy; Pinnacle Biologics Inc.CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic CancerUnited States
-
Taoyuan General HospitalUnknownNon-small Cell Lung Cancer (NSCLC) | Lung Metastasis
-
Roswell Park Cancer InstituteLumeda,Inc.Active, not recruitingMalignant Mesothelioma | Non-Small Cell Lung Carcinoma | Pleural DisorderUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Pinnacle Biologics Inc.; Simphotek Inc.RecruitingSmall Cell Lung Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Non-Small Cell Lung Carcinoma | Locally Advanced Lung CarcinomaUnited States
-
Roswell Park Cancer InstituteRecruitingLung Non-Small Cell Carcinoma | Pleural DisorderUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the GallbladderUnited States, Canada